Another issue that the Editors of JBR consider of great importance is research and publication ethics. This includes data fabrication/falsification/misinterpretation, disclosing of relevant personal or financial interests, plagiarism, and protection of sensitive and confidential data. BioMed Central is a member of, and subscribes to the principles of, COPE (Committee on Publication Ethics) [8] , and provides Editors with access to CrossCheck software for plagiarism detection. In addition, BioMed Central assures the fast publication of accepted manuscripts in its final citation, and also gives authors the opportunity to publish large datasets, video and large numbers of color illustrations for no additional charge [9] .
JBR carries the valuable (and variable) lessons learned during its first ten years of life over to a fresh new start brimming with new challenges and responsibilities, as well as opportunities. With an enriched set of article types (Research, Reviews, Short Reports, Hypotheses, Letters to the Editor, Commentaries and Book Reviews), the journal now provides additional podia through which authors may communicate their research and ideas in more flexible and exciting ways. Reflecting the broad expertise of the Editorial Board and the philosophy of its Editors, JBR continues on the same track of a multidisciplinary scope within biology. We hope that the broad coverage also incites authors to submit interesting works of an interdisciplinary/integrative nature. Within this general biological scope, the Editors of the journal will publish series devoted to popular topics such as evolutionary biology and molecular ecology.
JBR is run by practicing scientists, who are recognized academics that continue to publish and serve as reviewers for other journals. Therefore, authors and JBR staff (across all levels of responsibility, from the Editor-in-Chief to the Editorial Board) share common interests. Neither subsidiaries nor any scientific society endorse JBR. Within this structure the question of novelty in scientific research is fundamental. The criteria of novelty have been hotly debated over the years [10] , more so nowadays as some feel that the open access publishing model threatens to redefine them. JBR does not intend to be defiant of nor enticed by the metric of Impact Factor. As scientists judge scientists, it is useful to keep in mind that scientific progress is mainly incremental and occasionally interrupted by leaps of novelty.
JBR now enters a new exciting period of wider exposure and rigorous assessment. The Editors of JBR intend to follow the same principles that guided them to date in keeping on a tangent line with scientific progress and ethics of publishing.
